Patent · US Active

Method for reducing the expression of NKCC1 in a subject

US11427836B2 · kind B2 · utility

0Cited by

3References

15Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITE D'EVRY VAL D'ESSONNE · FR
GENETHON · FR
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · IT
FONDAZIONE TELETHON · IT

Inventors

Federico Mingozzi · Paris, FR
GIUSEPPE RONZITTI · Fontainebleau, FR
Andrea Contestabile · Ciambrin, IT
Laura Cancedda · Genova, IT

Key dates

Filing date	Apr 11, 2018
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Aug 28, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/531
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.